Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
1 other identifier
interventional
2,221
3 countries
33
Brief Summary
The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2007
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2007
CompletedFirst Submitted
Initial submission to the registry
October 30, 2007
CompletedFirst Posted
Study publicly available on registry
October 31, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedResults Posted
Study results publicly available
March 16, 2022
CompletedMay 3, 2022
April 1, 2022
2 years
October 30, 2007
February 16, 2022
April 11, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants With Pregnancy
The rate of pregnancy in women who received emergency contraception within 72 h of unprotected sexual intercourse.
Within 72 hours of unprotected Intercourse
Secondary Outcomes (2)
Actual Pregnancy Rate Compared to Expected Pregnancy Rate
Within 120 hours of unprotected Intercourse
Menstrual Bleeding Patterns
within the menstrual cycle of the unprotected Intercourse
Study Arms (2)
CDB-2914
EXPERIMENTALLevonorgestrel
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- women 16 or older in UK(except Northern Ireland) sites, 17 years or more in Northern Ireland (UK) and 18 years or more in Ireland and US
- present within 120 hours of unprotected intercourse
- regular menstrual cycles
- No current use of hormonal contraception
- Willing to not use hormonal methods of contraception until study completion
- At least one complete menstrual cycle (2 menses) post miscarriage, delivery or abortion
- For women who present more than 72 hours after intercourse, decline the insertion of an Intra Uterine Device for emergency contraception
- Able to provide informed consent
- Willing to abstain from further acts of unprotected intercourse until study completion
You may not qualify if:
- One or more acts of unprotected intercourse more than 120 hours
- current or recent use of hormonal methods of contraception
- currently pregnant or breastfeeding
- tubal ligation or current use of IUD
- Use of hormonal emergency contraception since last menstrual period
- Current use of IUD
- Tubal ligation
- Partner with a vasectomy
- Unsure about the date of the last menstrual period
- Severe asthma insufficiently controlled by oral glucocorticoid
- Hypersensitivity to the active substance levonorgestrel or any of the excipients of the drug products used in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- HRA Pharmalead
Study Sites (33)
Planned Parenthood Hollywood
Los Angeles, California, United States
Planned Parenthood Santa Monica
Santa Monica, California, United States
Planned Parenthood of the Rocky Mountains
Boulder, Colorado, United States
Planned Parenthood of the Rocky Mountains
Denver, Colorado, United States
Planned Parenthood of the Rocky Mountains
Littleton, Colorado, United States
Planned Parenthood of Greater Miami
Lake Worth, Florida, United States
Planned Parenthood of Greater Miami
Miami, Florida, United States
Planned Parenthood of Greater Miami
North Miami, Florida, United States
Planned Parenthood of Greater Miami
Stuart, Florida, United States
Planned Parenthood of Greater Miami
West Palm Beach, Florida, United States
Planned Parenthood of Northeast Ohio Akron Health Center
Akron, Ohio, United States
Planned Parenthood of Northeast Ohio Bedford Health Center
Bedford, Ohio, United States
Planned Parenthood of Northeast Ohio East Cleveland Health Center
Cleveland, Ohio, United States
Planned Parenthood of Northeast Ohio Old Brooklyn Health Center
Cleveland, Ohio, United States
Planned Parenthood of Northeast Ohio Kent Health Center
Kent, Ohio, United States
Planned Parenthood of Northeast Ohio Rocky River Health Center
Rocky River, Ohio, United States
Planned Parenthood of Texas Capitol Region
Austin, Texas, United States
Fannin Health Center
Houston, Texas, United States
Planned Parenthood of Houston and Southeast Texas Research Department
Houston, Texas, United States
Planned Parenthood Association of Utah
Ogden, Utah, United States
Planned Parenthood Association of Utah
Orem, Utah, United States
Planned Parenthood Association of Utah
Salt Lake City, Utah, United States
Planned Parenthood Association of Utah
West Valley City, Utah, United States
Well Woman Centre
Dublin, Ireland
NHS Grampian Sexual and Reproductive Health
Aberdeen, United Kingdom
Brook Family Planning Clinic
Belfast, United Kingdom
NHS Lothian Family Planning Service
Edinburgh, United Kingdom
NHS Greater Glasgow & Clyde Family Planning Service
Glasgow, United Kingdom
Liverpool PCT Family Planning Services
Liverpool, United Kingdom
London Sexual and Reproductive Health
London, United Kingdom
Manchester Primary Care Trust
Manchester, United Kingdom
Nottingham Contraception & Sexual Health Service
Nottingham, United Kingdom
Oxfordshire PCT Community Health
Oxford, United Kingdom
Related Publications (1)
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010 Feb 13;375(9714):555-62. doi: 10.1016/S0140-6736(10)60101-8. Epub 2010 Jan 29.
PMID: 20116841RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Henri Mathé
- Organization
- HRA Pharma
Study Officials
- PRINCIPAL INVESTIGATOR
Anna F Glasier, MD
NHS Lothian Family Planning Service
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 30, 2007
First Posted
October 31, 2007
Study Start
April 1, 2007
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
May 3, 2022
Results First Posted
March 16, 2022
Record last verified: 2022-04